Haleon: GSK's spun-off global consumer health giant, building a brand moat from Fenbid to Caltrate

Origin

In 2018, GSK announced plans to demerge its global consumer health business into an independent company. The core motivation was that prescription drug R&D required massive capital investments, while the consumer health business had long been viewed as an internal cash-cow supporting player rather than a strategic protagonist, resulting in restricted resource allocation. In 2019, GSK reached an agreement with Pfizer to combine their consumer health businesses into a joint venture, with GSK holding 68% and Pfizer 32%. With annual revenue of approximately 9.8 billion pounds post-merger, it became one of the world's largest OTC consumer health enterprises, paving the way for its ultimate independent listing.

Milestones

Turning Points

• The 2019 merger with Pfizer to form the world's largest consumer health joint venture was a decisive step in scaling up.
• Rejecting Unilever's bid of approximately 50 billion pounds in 2022 to pursue an independent listing transformed a one-time cash-out into a long-term value bet.
• Completing the demerger and dual listing in July 2022 transitioned the entity from an internal corporate department into an independent, publicly traded company responsible for its own profits and losses.
• Establishing both China and the United States as must-win markets after 2025, achieving wholly-owned control by acquiring the remaining equity in Sino-American SmithKline.

Failures & Pitfalls

• The listing debuted to a cold reception, with the market capitalization on its first day of trading in July 2022 falling below Unilever's prior 50 billion pound bid, as the market voted with its feet to question the demerger decision.
• Carrying approximately 10 billion pounds in net debt at the time of the demerger, high leverage significantly suppressed valuation and dividend capacity amid a rising interest rate cycle.
• Parallel operation of multiple brands and systems during the 2014 integration of Novartis's consumer health assets led to runaway synergy costs, with synergy realization falling far slower than expected.
• Volume growth with price declines occurred in the Asia-Pacific region in the first half of 2026, featuring negative price contributions and exposing a decline in growth quality as channel structures tilted toward channels with weaker pricing power.

Core Data

• 上市当日市值：Approximately 30.5 billion pounds (based on public data sources, independent verification unverified)
• 净资产债务规模：Approximately 10 billion pounds in net debt at demerger (based on public data sources, independent verification unverified)
• 年营收规模：Approximately 11 billion pounds (based on public data sources, independent verification unverified)
• 核心品牌数量：9 brands (based on public data sources, independent verification unverified)
• 中国地位：Largest multinational consumer healthcare company in China (based on public data sources, independent verification unverified)
• 合资估值：Annual sales of approximately 9.8 billion pounds upon 2019 consumer health business merger (based on public data sources, independent verification unverified)
• 股权结构变化：GSK and Pfizer gradually liquidated and exited all shareholdings post-listing (based on public data sources, independent verification unverified)

Competitors / Peers

In the global OTC and consumer healthcare sector, Haleon benchmarks against Bayer Consumer Health, Kenvue (spun off from Johnson & Johnson, featuring Tylenol and Neutrogena), Sanofi's consumer health business Opella, and traditional rival Procter & Gamble's healthcare division. Kenvue was spun off from Johnson & Johnson in 2023 following a path highly similar to Haleon's, with the two locking in direct combat in analgesics and oral care categories; Bayer Consumer Health boasts Aspirin and Elevit with deep roots in the European market; whereas in the Chinese market, it faces dual squeeze in channels and pricing from domestic pharmaceutical peers such as Yiling Pharmaceutical, China Resources Sanjiu, and Yunnan Baiyao, alongside health supplement companies like By-Health.